NextCure Inc

NXTC

Company Profile

  • Business description

    NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.

  • Contact

    9000 Virginia Manor Road
    Suite 200
    BeltsvilleMD20705
    USA

    T: +1 240 399-4900

    https://www.nextcure.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    43

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.702.300.03%
CAC 407,715.607.87-0.10%
DAX 4024,084.8611.190.05%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,811.615.080.06%
HKSE24,134.74246.911.03%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,688.81101.130.26%
NZX 50 Index12,859.0294.070.74%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,590.701.400.02%
SSE Composite Index3,497.4824.350.70%

Market Movers